Scleroderma Comprehensive Plus Profile (RDL)
Use
The new Scleroderma Comprehensive Plus Profile is the most comprehensive Scleroderma panel available on the market, and when combined with typical clinical features, can assist in the diagnosis and management of early or established disease. Identifying autoantibodies earlier in the disease can aid in diagnosis, prognosis and predicting the risk for end-stage organ complications, allowing for more aggressive intervention. In Scleroderma patients, anti-PM/Scl-75 and anti-PM/Scl-100 antibodies can be found in diffuse or limited cutaneous disease. The presence of both antibodies is highly associated with inflammatory Myositis.
Special Instructions
Separate serum from cells within one hour of collection and transfer to a plastic transport tube before shipping. Testing schedules may vary.
Limitations
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the FDA. EIA testing can yield false positives, therefore, all EIA positive tests are confirmed with a second method. Some autoantibodies may be associated with several autoimmune conditions and can provide limited specificity to a particular disease.
Methodology
Immunoassay
Biomarkers
LOINC Codes
- 42254-3
- 5077-3
- 63329-7
- 26975-3
- 57662-9
- 49963-2
- 81743-7
- 101221-0
- 88736-4
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
4 mL
Minimum Volume
3 mL
Container
Red-top tube or gel-barrier tube
Collection Instructions
Separate serum from cells within one hour of collection. Transfer to a plastic transport tube before shipping.
Storage Instructions
Refrigerate.
Causes for Rejection
Grossly hemolyzed; bacterial contamination; lipemic specimen; icteric specimen; non-serum specimen types
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 60 days |